United States Department of Justice Antitrust Division

Dr. Joanna Tsai Joins Cornerstone Research as Vice President

Retrieved on: 
Giovedì, Ottobre 19, 2023

WASHINGTON, Oct. 19, 2023 /PRNewswire-PRWeb/ -- Cornerstone Research, a leading provider of economic and financial consulting and expert testimony, today announced that Dr. Joanna Tsai has joined the firm as a vice president, based in the Washington, DC, office.

Key Points: 
  • WASHINGTON, Oct. 19, 2023 /PRNewswire-PRWeb/ -- Cornerstone Research, a leading provider of economic and financial consulting and expert testimony, today announced that Dr. Joanna Tsai has joined the firm as a vice president, based in the Washington, DC, office.
  • Dr. Tsai will cohead Cornerstone Research's merger investigations practice in Washington, DC.
  • Dr. Tsai brings nearly twenty years of experience in private practice, government, and academia.
  • "Cornerstone Research is widely recognized for its exceptional work across a range of consequential transactions," Dr. Tsai said.

Berger Montague Expands Its Premier Antitrust Practice with Addition of Two Attorneys

Retrieved on: 
Giovedì, Settembre 28, 2023

PHILADELPHIA, Sept. 28, 2023 /PRNewswire/ -- Complex litigation powerhouse Berger Montague is pleased to announce that the firm has bolstered its antitrust practice with the addition of Zachary Caplan as a Shareholder and Grace Ann Brew as an Associate. Both new additions will work out of the firm's Philadelphia headquarters.

Key Points: 
  • PHILADELPHIA, Sept. 28, 2023 /PRNewswire/ -- Complex litigation powerhouse Berger Montague is pleased to announce that the firm has bolstered its antitrust practice with the addition of Zachary Caplan as a Shareholder and Grace Ann Brew as an Associate.
  • In the last year alone, the firm has added more than a dozen attorneys and opened three new offices.
  • Mr. Caplan returns to Berger Montague following a year and a half of service with the Antitrust Division of the U.S. Department of Justice.
  • The addition of Zach and Grace Ann is further evidence that Berger Montague is succeeding in creating an environment where thoughtful, creative, aggressive, and diligent attorneys seek to practice."

Manatt Welcomes Former DOJ Antitrust Enforcer in Washington, D.C.

Retrieved on: 
Martedì, Settembre 12, 2023

At the Antitrust Division, Carson was one of the key trial lawyers in courtroom challenges to two of the largest mergers in history, and is on the short list of antitrust attorneys to have successfully prosecuted and defended high-stakes merger trials.

Key Points: 
  • At the Antitrust Division, Carson was one of the key trial lawyers in courtroom challenges to two of the largest mergers in history, and is on the short list of antitrust attorneys to have successfully prosecuted and defended high-stakes merger trials.
  • Carson brings extensive experience representing clients in antitrust and competition matters before federal and state antitrust enforcers—including the Antitrust Division, the Federal Trade Commission (FTC), and state attorneys general—including merger and conduct investigations and litigation.
  • He also provides clients with strategic competition law counseling that minimizes risks associated with transactions among competitors and other third parties.
  • He was also honored with the Assistant Attorney General Award of Distinction—the highest Antitrust Division performance award—three years in a row for his investigation and litigation efforts.

FTC Votes to Issue Statement Withdrawing Prior Pharmacy Benefit Manager Advocacy

Retrieved on: 
Giovedì, Luglio 20, 2023

The Federal Trade Commission voted to issue a statement cautioning against reliance on prior advocacy statements and studies related to pharmacy benefit mangers (PBMs) that no longer reflect current market realities.

Key Points: 
  • The Federal Trade Commission voted to issue a statement cautioning against reliance on prior advocacy statements and studies related to pharmacy benefit mangers (PBMs) that no longer reflect current market realities.
  • The Commission’s statement warns against relying on nine advocacy letters published or issued between 2004 and 2014 that advocated against proposals to increase regulatory oversight and transparency of PBMs.
  • The Commission voted 3-0 during an open meeting to issue the statement withdrawing prior PBM advocacy.
  • For the latest news and resources, follow the FTC on social media, subscribe to press releases and read our blog.

FTC Votes to Issue Statement Withdrawing Prior Pharmacy Benefit Manager Advocacy

Retrieved on: 
Giovedì, Luglio 20, 2023

The Federal Trade Commission voted to issue a statement cautioning against reliance on prior advocacy statements and studies related to pharmacy benefit mangers (PBMs) that no longer reflect current market realities.

Key Points: 
  • The Federal Trade Commission voted to issue a statement cautioning against reliance on prior advocacy statements and studies related to pharmacy benefit mangers (PBMs) that no longer reflect current market realities.
  • The Commission’s statement warns against relying on nine advocacy letters published or issued between 2004 and 2014 that advocated against proposals to increase regulatory oversight and transparency of PBMs.
  • The Commission voted 3-0 during an open meeting to issue the statement withdrawing prior PBM advocacy.
  • For the latest news and resources, follow the FTC on social media, subscribe to press releases and read our blog.

FTC and DOJ Seek Comment on Draft Merger Guidelines

Retrieved on: 
Mercoledì, Luglio 19, 2023

Proposed guidelines would address the many ways mergers can weaken competition, harming consumers, workers, and businesses

Key Points: 


Proposed guidelines would address the many ways mergers can weaken competition, harming consumers, workers, and businesses
Today, the Federal Trade Commission and the Department of Justice are releasing a draft update of the Merger Guidelines, which describe and guide the agencies’ review of mergers and acq

FTC and DOJ Seek Comment on Draft Merger Guidelines

Retrieved on: 
Mercoledì, Luglio 19, 2023

Both agencies encourage the public to review the draft and provide feedback through a public comment period that will last 60 days.

Key Points: 
  • Both agencies encourage the public to review the draft and provide feedback through a public comment period that will last 60 days.
  • “With these draft Merger Guidelines, we are updating our enforcement manual to reflect the realities of how firms do business in the modern economy.
  • Today, we are issuing draft guidelines that are faithful to the law, which prevents mergers that threaten competition or tend to create monopolies.
  • The draft guidelines build upon, expand, and clarify frameworks set out in previous versions.
  • These guidelines are not mutually exclusive, and a given merger may implicate multiple guidelines.
  • In January 2022, the agencies announced a broad initiative to evaluate potential updates and revisions to the Horizontal Merger Guidelines, issued in 2010, and the Vertical Merger Guidelines issued in 2020.
  •  The draft Merger Guidelines also make clear that they are not a substitute for the law itself, and do not create new rights or obligations.
  • The agencies will use the public comments to evaluate and update the draft before finalizing the guidelines.
  • Visit the fact sheet on Draft Merger Guidelines.

FTC and DOJ Propose Changes to HSR Form for More Effective, Efficient Merger Review

Retrieved on: 
Martedì, Giugno 27, 2023

The proposed changes to the HSR Form and instructions would enable the Agencies to more effectively and efficiently screen transactions for potential competition issues within the initial waiting period, which is typically 30 days.

Key Points: 
  • The proposed changes to the HSR Form and instructions would enable the Agencies to more effectively and efficiently screen transactions for potential competition issues within the initial waiting period, which is typically 30 days.
  • This initial competition review is critical for the agencies to identify transactions that require an in-depth investigation.
  • The Commission vote to publish for public comment the Notice of Proposed Rulemaking containing proposed amendments to the HSR Rules was 3-0.
  • For the latest news and resources, follow the FTC on social media, subscribe to press releases and read our blog.

FTC and DOJ Propose Changes to HSR Form for More Effective, Efficient Merger Review

Retrieved on: 
Martedì, Giugno 27, 2023

The proposed changes to the HSR Form and instructions would enable the Agencies to more effectively and efficiently screen transactions for potential competition issues within the initial waiting period, which is typically 30 days.

Key Points: 
  • The proposed changes to the HSR Form and instructions would enable the Agencies to more effectively and efficiently screen transactions for potential competition issues within the initial waiting period, which is typically 30 days.
  • This initial competition review is critical for the agencies to identify transactions that require an in-depth investigation.
  • The Commission vote to publish for public comment the Notice of Proposed Rulemaking containing proposed amendments to the HSR Rules was 3-0.
  • For the latest news and resources, follow the FTC on social media, subscribe to press releases and read our blog.

FTC, DOJ Issue Summary on Joint Pharmaceutical Merger Analysis Workshop

Retrieved on: 
Giovedì, Giugno 1, 2023

The workshop, which took place June 14-June 15, 2022, brought together FTC and DOJ staff, offices of state attorneys general, international enforcement partners, academics, and other experts.

Key Points: 
  • The workshop, which took place June 14-June 15, 2022, brought together FTC and DOJ staff, offices of state attorneys general, international enforcement partners, academics, and other experts.
  • It served as a culmination of the Multilateral Pharmaceutical Merger Task Force, an effort to rethink the approaches to pharmaceutical merger review formed by then-Acting Chairwoman Rebecca Kelly Slaughter.
  • The workshop summary describes each speaker’s remarks and provides an overview of panel discussions on market concentration in the pharmaceutical sector, merger remedies, innovation aspects of pharmaceutical mergers, and the intersection between conduct by pharmaceutical companies and merger analysis.
  • The summary also includes an appendix of ideas stemming from the workshop discussions.